Allotex
Allotex is an ophthalmic biologics company developing TransForm, a platform of precisely-shaped allogenic corneal lenticules that function as permanent living contact lenses to treat presbyopia, hyperopia, and myopia, sold direct to refractive surgeons and ophthalmology clinics.
- Company typePrivate
- Founded2016
- HeadquartersBoston, United States
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What Allotex does
Allotex is an ophthalmic biologics and device company developing therapeutic solutions for presbyopia, hyperopia, and myopia through tissue addition technology. The company was founded by Drs. Michael Mrochen and David Muller and operates through two legal entities — Allotex, Inc. (US, Boston) and Allotex Italia S.p.A. (Italy, Milan). Its core product platform, TransForm, consists of precisely-shaped human corneal allografts (lenticules) 2–3.5 mm in diameter with 15–25 microns central thickness, processed using excimer laser shaping and validated electron beam terminal sterilization to produce acellular, shelf-stable (two years at room temperature) tissue implants. The lenticules are implanted under a femtosecond laser-created corneal flap, functioning as a permanent living contact lens, with the procedure described as minimally invasive, removable, and replaceable. Clinical findings cited by the company include an average improvement of 5 lines in near vision for emmetropic presbyopic patients without significantly affecting distance vision.
Allotex sources its raw corneal tissue from VisionGift, an EBAA-approved eye bank, with tissue undergoing aseptic recovery, precise laser shaping, and terminal electron beam irradiation before distribution. Its proprietary technology stack — combining excimer laser precision, OCT-based measurement, and shelf-stable sterile cornea — is positioned as resolving historical limitations of tissue addition first explored by Dr. Barraquer in 1949, particularly imprecise sculpting and limited tissue shelf life.
The company sells TransForm lenticules direct to refractive surgeons, ophthalmology clinics, and hospital eye departments through enterprise field sales. Pricing is not publicly disclosed and is structured as one-time B2B product sales to medical facilities. Allotex launched TransForm commercially in Europe in early 2024, commenced FDA-monitored US clinical trials in 2024, and supports adoption via medical conference presence (ESCRS, ASCRS), peer-reviewed publications, KOL engagement, and clinical trial partnerships (e.g., Vance Thompson Vision). The company has raised a $30 million Series B financing (July 2023, first close) led by KCK Medtech, with participation from Panakes Partners, Junson Capital, EXOR, Exor Ventures, and Supernova Invest.
Allotex firmographics
Firmographics- Name
- Allotex
- Legal name
- Allotex Italia S.p.A. and Allotex, Inc.
- Website
- https://allotex.com
- Company type
- Private
- Founded year
- 2016
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Allotex is an ophthalmic biologics company developing TransForm, a platform of precisely-shaped allogenic corneal lenticules that function as permanent living contact lenses to treat presbyopia, hyperopia, and myopia, sold direct to refractive surgeons and ophthalmology clinics.
- Ownership category
- akta.pro rank
Allotex industry classification
Industry- Product category
- Ophthalmic Medical Devices — Corneal Inlays for Refractive Surgery
- NAICS
- Surgical Appliance and Supplies Manufacturing (339113), Surgical and Medical Instrument Manufacturing (339112), Ophthalmic Goods Manufacturing (339115)
- SIC
- Surgical & Medical Instruments & Apparatus (3841), Ophthalmic Goods (3851)
- akta.pro primary industry
- Cornea & External Disease Surgical Devices (Keratoplasty Tools, Cross-Linking Systems, Amniotic Membrane Delivery) (HLAHAJAK)
- akta.pro secondary industries
- Refractive Surgery Systems (Excimer/Femtosecond Lasers, Phakic IOL Systems, Wavefront/Guidance) (HLAHAJAG), Allergen Immunotherapy (SCIT/SLIT) Services (HLAKAAAF)
Keywords
Where Allotex is headquartered
LocationHeadquarters
- HQ city
- Boston
- HQ country
- United States
- HQ region
- North America
Offices2 records
Markets served
Allotex business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Supply Chain, Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
Revenue model
- TransForm Corneal Inlay Sales: Sale of precision-shaped allogenic corneal lenticules to refractive surgeons and ophthalmology practices for implantation in patients with presbyopia, hyperopia, and myopia. Revenue derived from product sales to medical facilities.
Go-to-market motion1 record
Distribution channels2 records
Marketing channels4 records
Allotex product offering
Product offeringCore offering
Allotex manufactures and sells TransForm™ — precision-shaped, electron-beam-sterilized human corneal allograft lenticules (inlays and onlays) implanted under a femtosecond laser-created corneal flap to correct presbyopia, hyperopia, and myopia. The product is sold to refractive surgeons, ophthalmology clinics, and hospital eye departments as a biocompatible, removable, shelf-stable alternative to synthetic corneal implants and tissue-removal laser procedures.
Product overview
Allotex is an ophthalmic biologics company offering a portfolio of allograft corneal inlay products centered on its TransForm™ platform. TransForm is a precisely-shaped human corneal allograft (lenticule) designed to correct presbyopia, hyperopia, and myopia through tissue addition technology. The product is implanted under a femtosecond laser-created corneal flap and creates what essentially functions as a permanent, living contact lens. The portfolio includes TransForm Inlays and Onlays for various refractive corrections, all sharing the core technology of electron beam-sterilized, shelf-stable allogenic corneal tissue shaped using excimer laser technology.
Differentiator
Problem solved
Functional benefit
Products and services
- TransForm Allogenic Corneal Inlays and Onlays Precisely-shaped, electron-beam-sterilized human corneal allograft lenticules (2–3.5mm in diameter, 15–25 microns central thickness) implanted under a femtosecond laser-created corneal flap. 100% biocompatible, acellular, two-year shelf-stable at room temperature, and fully removable/replaceable. Used by refractive surgeons and ophthalmologists to create a permanent living contact lens effect for vision correction.
Companies that use Allotex
Customer profileNamed customers1 record
Segments2 records
Ideal customer profiles1 record
Allotex technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability1 record
Feature3 records
Allotex partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- VisionGiftcoreEye bank partner providing human corneal tissue sourced under strict ethical standards from EBAA-approved facilities. VisionGift supplies sterile corneas with two-year shelf stability that undergo validated electron beam sterilization before processing into TransForm lenticules.
Scale indicators3 records
Recent moves7 records
Expansion highlights5 records
Allotex competitors and assessment
Company assessmentDirect peers
- AcuFocus: Developer of the Kamra small-aperture corneal inlay, the most direct commercial analog to Allotex's TransForm for surgical presbyopia correction. Competes for the same refractive surgeon channel and patient demographic.
- Presbia: Developed the Flexivue Microlens, a refractive corneal inlay for presbyopia. Closely comparable in product category (small-aperture corneal inlay) and target indication, providing a relevant benchmark for inlay commercial dynamics.
- Lenz Therapeutics: Late-stage developer of pharmacological presbyopia therapies (e.g., aceclidine-based drops). Competes for the same presbyopia patient pool via a non-surgical mechanism and represents the most active emerging alternative to surgical inlays.
- Orasis Pharmaceuticals: Developer of presbyopia-correcting eye drop therapies (e.g., CSF-1). Targets the same patient need (near-vision correction without reading glasses) via a non-surgical route, directly competing for patient demand and physician mindshare.
Broad incumbents
- Alcon: Global ophthalmic incumbent offering LASIK platforms (WaveLight), IOLs, and (via Vuity acquisition) presbyopia eye drops. Sets the standard for refractive surgeon relationships and commercial scale that Allotex must contend with.
- Johnson & Johnson Vision: Operates a leading LASIK refractive surgery platform (iDesign, IntraLase) and broad cataract/IOL portfolio. Represents the incumbent refractive surgery standard of care and competes for surgeon chair time.
- Bausch + Lomb: Diversified ophthalmic device and pharmaceutical company with refractive surgery, IOL, and pharmaceutical offerings. Competes broadly across the ophthalmic workflow that Allotex is entering.
- STAAR Surgical: Maker of the Visian ICL (Implantable Collamer Lens) for myopia correction. Competes for the same refractive surgery channel with an alternative implantable lens-based approach to vision correction.
Emerging players
- ViewPoint Therapeutics: Early-stage developer of therapeutics targeting crystallin proteins to treat presbyopia and cataracts. A relevant emerging competitor pursuing non-surgical or pharmacologic correction of the same underlying indication.
- Lensar: Developer of femtosecond laser cataract and refractive surgery platforms. Operates in the same surgeon-installed-base channel as Allotex and is an indirect competitor via premium refractive procedure offerings.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat4 records
Key risks6 records
Key highlights6 records
Customer concentration
Allotex social profiles
Digital presenceAllotex compliance and trust
Trust signalCompliance2 records
Allotex financial estimates
Financial estimateRevenue estimate
Valuation estimate
Allotex leadership team
Management profileNumber of profiles
Profiles11 records
Allotex funding detail
Funding detailFunding overview
Funding rounds1 record
Investors5 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Allotex M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Allotex
What does Allotex do?
Allotex manufactures and sells TransForm™ — precision-shaped, electron-beam-sterilized human corneal allograft lenticules (inlays and onlays) implanted under a femtosecond laser-created corneal flap to correct presbyopia, hyperopia, and myopia. The product is sold to refractive surgeons, ophthalmology clinics, and hospital eye departments as a biocompatible, removable, shelf-stable alternative to synthetic corneal implants and tissue-removal laser procedures.
Is Allotex a public or private company?
Allotex is a private company. It is classified as venture growth investor backed and is currently operating.
When was Allotex founded?
Allotex was founded in 2016. It employs 11 to 50 people.
Where is Allotex based?
Allotex is headquartered in Boston, United States, in the North America region.
How does Allotex make money?
One revenue line is on record: transForm Corneal Inlay Sales.
Who are Allotex's main competitors?
Direct peers on record are AcuFocus, Presbia, Lenz Therapeutics and Orasis Pharmaceuticals. Broad incumbents are Alcon, Johnson & Johnson Vision, Bausch + Lomb and STAAR Surgical. Emerging players are ViewPoint Therapeutics and Lensar.
Does Allotex have an API?
No public API is recorded for Allotex.
What industry is Allotex in?
Allotex's product category is Ophthalmic Medical Devices — Corneal Inlays for Refractive Surgery. Its primary akta.pro industry code is HLAHAJAK, Cornea & External Disease Surgical Devices (Keratoplasty Tools, Cross-Linking Systems, Amniotic Membrane Delivery), with a secondary code of HLAHAJAG, Refractive Surgery Systems (Excimer/Femtosecond Lasers, Phakic IOL Systems, Wavefront/Guidance). Its NAICS code is 339113 and its SIC code is 3841.